Skip to main content
Clinical Trials/NCT01746667
NCT01746667
Completed
Not Applicable

Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia

VU University of Amsterdam1 site in 1 country70 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Social Anxiety Disorder
Sponsor
VU University of Amsterdam
Enrollment
70
Locations
1
Primary Endpoint
Change from baseline: Liebowitz Social Anxiety Scale-Self report
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The current study aims at comparing the efficacy of exposure in vivo and exposure via virtual reality for social anxiety disorder. 70 patients with social anxiety disorder will be randomized to either one of the active conditions or to a waiting-list condition. Participants on the waiting-list will be offered either exposure in vivo of in virtual reality after a waiting period of five weeks. Levels of psychopathology will be assessed at pre- and post-treatment as well as three and 12 months after treatment.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
August 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
VU University of Amsterdam
Responsible Party
Principal Investigator
Principal Investigator

Paul M.G.Emmelkamp

Professor

VU University of Amsterdam

Eligibility Criteria

Inclusion Criteria

  • 18 - 65 years old
  • a primary diagnosis of social anxiety disorder as measured with the SCID
  • fluency in Dutch.

Exclusion Criteria

  • psychotic episodes in the past, suicidal intentions or substance dependence.
  • behavior therapy in the preceding one year.

Outcomes

Primary Outcomes

Change from baseline: Liebowitz Social Anxiety Scale-Self report

Time Frame: Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up.

Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.

Change from baseline: Fear of Negative Evaluation Scale

Time Frame: Pre-treatment to post-treatment (5 weeks), three months follow-up, and 12 months follow-up.

Change from pre-treatment to post-treatment (5 weeks), 3 months follow-up and 12 months follow-up.

Secondary Outcomes

  • Change from baseline: Behavioral Assessment Task (BAT), Public Speaking Performance Scale(Pre-treatment to post-treatment (5 weeks))
  • Change from baseline: Structured Clinical Interview for DSM-IV (Social Phobia Module)(Pre-treatment to three months follow-up.)
  • Change from baseline: Depression Anxiety Stress Scale(Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up.)
  • Change from baseline: Personality Disorder Belief Questionnaire(Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up.)
  • Change from baseline: Eurohis Quality of Life Scale(Pre-treatment to post-treatment (5 weeks), three months follow-up, 12 months follow-up.)

Study Sites (1)

Loading locations...

Similar Trials